Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of a Selective FGFR2/3 Inhibitor, CGT4859, in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors Harboring FGFR2 and/or FGFR3 Genetic Alterations

NCT06777316 is registered in ClinicalTrials.gov with Cogent Biosciences, Inc. as lead sponsor.

NCT NCT06777316
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06777316 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of a Selective FGFR2/3 Inhibitor, CGT4859, in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors Harboring FGFR2 and/or FGFR3 Genetic Alterations
Lead sponsor
Cogent Biosciences, Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
January 22, 2025
Completion date
June 30, 2027
Enrollment
110 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, cholangiocarcinoma, fgfr2 gene amplification, fgfr2 gene fusion/rearrangement, fgfr2 gene short variants, fgfr2 genetic alterations, fgfr3 gene amplification, fgfr3 gene fusion/rearrangement, fgfr3 gene short variants, fgfr3 genetic alterations, intrahepatic cholangiocarcinoma (icc), other solid tumors, adult